Q-omics provides the consensus-scored ARL5AP4 profile across patient tissues and cancer cell-line models. ARL5AP4 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ARL5AP4 is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, ARL5AP4 RNA expression shows 6,105 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, LUSC, and STAD as cancer lineages where ARL5AP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARL5AP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARL5AP4 survival associations across molecular data types. ARL5AP4 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARL5AP4 RNA expression–survival associations across cancer types. High ARL5AP4 expression shows unfavorable associations in KIRP, UVM, LUSC and READ, but favorable associations in COAD and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for ARL5AP4 RNA expression.
This table summarizes ARL5AP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ARL5AP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARL5AP4 shows lower tumor expression in LUSC, LUAD, READ and KIRC and higher tumor expression in COAD and HNSC. The LUSC box plot shows higher ARL5AP4 RNA expression in normal versus tumor tissue (log2 FC = −0.260, t-test p < 0.001).
This table shows molecular features associated with ARL5AP4 in patient tissues and cancer cell lines. In patient samples, ARL5AP4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
